|
Delayed
Sao Paulo
01:31:42 2026-10-16 pm EDT
|
5-day change | 1st Jan Change | ||
| 78.99 BRL | -2.12% |
|
+6.36% | +19.75% |
| 08:00am | EU Medicines Agency Panel Backs CuraTeQ Biologics' Neupogen Biosimilar for Neutropenia | MT |
| Oct. 15 | Goldman Sachs Adjusts Price Target on Amgen to $481 From $475 | MT |
| Market Cap | 235B 1,193B 209B 193B 176B 332B 22,270B 337B 2,324B 911B 11,621B 881B 862B 37,047B | P/E 2026 * |
27.6x | P/E 2027 * | 24.6x |
|---|---|---|---|---|---|
| Enterprise Value | 276B 1,404B 245B 227B 207B 390B 26,195B 397B 2,733B 1,072B 13,670B 1,036B 1,014B 43,577B | EV / Sales 2026 * |
7.08x | EV / Sales 2027 * | 6.68x |
| Free-Float |
99.77% | Yield 2026 * |
2.32% | Yield 2027 * | 2.46% |
Last Transcript: Amgen Inc.
| 1 day | -2.12% | ||
| 1 week | +6.36% | ||
| Current month | +0.97% | ||
| 1 month | +14.11% | ||
| 3 months | +17.53% | ||
| 6 months | +26.93% | ||
| Current year | +19.75% |
| 1 week | 73.99 |  | 79.84 |
| 1 month | 69.26 | | 79.84 |
| Current year | 48.4 | | 83.38 |
| 1 year | 48.4 | | 83.38 |
| 3 years | 45.12 | | 83.38 |
| 5 years | 37.52 | | 83.38 |
| 10 years | 15.78 | | 83.38 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 63 | 2012-04-30 |
| Director of Finance/CFO | 62 | 2010-05-12 | |
Paul Burton
CTO | Chief Tech/Sci/R&D Officer | 57 | 2023-05-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CHM | Chairman | 63 | 2012-12-31 |
Tyler Jacks
BRD | Director/Board Member | 65 | 2011-12-31 |
Robert Eckert
BRD | Director/Board Member | 71 | 2011-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.12% | +6.36% | - | - | 235B | |
| +0.11% | +6.35% | +53.06% | +103.38% | 1,116B | |
| +0.77% | -2.34% | +32.89% | +62.07% | 610B | |
| +0.74% | +3.12% | +25.67% | +93.64% | 501B | |
| +0.91% | +0.69% | +74.70% | +40.78% | 358B | |
| -0.13% | +5.98% | +32.91% | +50.39% | 366B | |
| -0.95% | +4.70% | +19.51% | +43.00% | 288B | |
| -1.98% | +3.73% | -0.86% | +13.43% | 261B | |
| -0.30% | +4.38% | +46.39% | +50.95% | 235B | |
| -0.96% | +3.14% | +32.30% | +96.87% | 195B | |
| Average | -0.41% | +5.27% | +35.18% | +61.61% | 436.64B | |
| Weighted average by Cap. | -0.05% | +4.93% | +39.06% | +71.23% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 38.97B 198B 34.64B 32.11B 29.22B 55.13B 3,699B 56.01B 386B 151B 1,930B 146B 143B 6,153B | 40.4B 205B 35.91B 33.28B 30.28B 57.14B 3,834B 58.06B 400B 157B 2,001B 152B 148B 6,378B |
| Net income | 8.54B 43.43B 7.59B 7.04B 6.4B 12.08B 811B 12.27B 84.58B 33.16B 423B 32.05B 31.37B 1,348B | 9.43B 47.93B 8.38B 7.77B 7.07B 13.33B 895B 13.55B 93.35B 36.6B 467B 35.38B 34.62B 1,488B |
| Net Debt | 41.36B 210B 36.76B 34.07B 31B 58.5B 3,925B 59.44B 410B 161B 2,048B 155B 152B 6,529B | 35.3B 179B 31.38B 29.08B 26.46B 49.93B 3,350B 50.73B 350B 137B 1,748B 132B 130B 5,573B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-16 | R$78.99 | -2.12% | 66 |
| 26-10-15 | R$79.65 | +3.44% | 177 |
| 26-10-14 | R$77.00 | +3.49% | 388 |
| 26-10-13 | R$74.40 | +0.18% | 85 |
| 26-10-09 | R$74.27 | -0.71% | 74 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- AMGN Stock
- AMGN34 Stock
Select your edition
All financial news and data tailored to specific country editions
